124 related articles for article (PubMed ID: 22204534)
1. Optimal design of mixed-effects PK/PD models based on differential equations.
Wang Y; Eskridge KM; Nadarajah S
J Biopharm Stat; 2012; 22(1):180-205. PubMed ID: 22204534
[TBL] [Abstract][Full Text] [Related]
2. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
Retout S; Mentré F; Bruno R
Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
[TBL] [Abstract][Full Text] [Related]
3. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
Nguyen TT; Bazzoli C; Mentré F
Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
[TBL] [Abstract][Full Text] [Related]
4. Comparison of robust criteria for D-optimal designs.
Foo LK; McGree J; Eccleston J; Duffull S
J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
[TBL] [Abstract][Full Text] [Related]
5. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
Bazzoli C; Retout S; Mentré F
Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
[TBL] [Abstract][Full Text] [Related]
6. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.
Bazzoli C; Retout S; Mentré F
Comput Methods Programs Biomed; 2010 Apr; 98(1):55-65. PubMed ID: 19892427
[TBL] [Abstract][Full Text] [Related]
7. Compound optimal design criteria for nonlinear models.
McGree JM; Eccleston JA; Duffull SB
J Biopharm Stat; 2008; 18(4):646-61. PubMed ID: 18607799
[TBL] [Abstract][Full Text] [Related]
8. A pragmatic approach to the design of population pharmacokinetic studies.
Roy A; Ette EI
AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two design optimality criteria applied to a nonlinear model.
Bogacka B; Wright F
J Biopharm Stat; 2004 Nov; 14(4):909-30. PubMed ID: 15587972
[TBL] [Abstract][Full Text] [Related]
10. Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
Loingeville F; Nguyen TT; Riviere MK; Mentré F
J Biopharm Stat; 2020; 30(1):31-45. PubMed ID: 31032703
[TBL] [Abstract][Full Text] [Related]
11. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
Foo LK; McGree J; Duffull S
Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
[TBL] [Abstract][Full Text] [Related]
12. Forcing function diagnostics for nonlinear dynamics.
Hooker G
Biometrics; 2009 Sep; 65(3):928-36. PubMed ID: 19210741
[TBL] [Abstract][Full Text] [Related]
13. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
Dumont C; Chenel M; Mentré F
J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
[TBL] [Abstract][Full Text] [Related]
14. Optimal experiment design for cardinal values estimation: guidelines for data collection.
Bernaerts K; Gysemans KP; Nhan Minh T; Van Impe JF
Int J Food Microbiol; 2005 Apr; 100(1-3):153-65. PubMed ID: 15854701
[TBL] [Abstract][Full Text] [Related]
15. Design of population pharmacokinetic experiments using prior information.
Ogungbenro K; Aarons L
Xenobiotica; 2007; 37(10-11):1311-30. PubMed ID: 17968747
[TBL] [Abstract][Full Text] [Related]
16. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments.
Ogungbenro K; Aarons L; Graham G
J Biopharm Stat; 2006; 16(2):135-50. PubMed ID: 16584063
[TBL] [Abstract][Full Text] [Related]
17. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.
Retout S; Duffull S; Mentré F
Comput Methods Programs Biomed; 2001 May; 65(2):141-51. PubMed ID: 11275334
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.
Mentré F; Dubruc C; Thénot JP
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):299-319. PubMed ID: 11468942
[TBL] [Abstract][Full Text] [Related]
19. D-optimal cohort designs for linear mixed-effects models.
Tekle FB; Tan FE; Berger MP
Stat Med; 2008 Jun; 27(14):2586-600. PubMed ID: 17726724
[TBL] [Abstract][Full Text] [Related]
20. Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.
Ogungbenro K; Graham G; Gueorguieva I; Aarons L
J Biopharm Stat; 2008; 18(2):342-58. PubMed ID: 18327725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
